Granules India Limited (BOM:532482)

Market Cap	136.05B
Revenue (ttm)	48.42B
Net Income (ttm)	5.13B
Shares Out	242.67M
EPS (ttm)	21.15
PE Ratio	26.51
Forward PE	21.25
Dividend	1.50 (0.26%)
Ex-Dividend Date	Jul 31, 2025

Volume	37,207
Average Volume	33,809
Open	569.00
Previous Close	566.55
Day's Range	551.45 - 569.00
52-Week Range	412.05 - 621.10
Beta	-0.11
RSI	52.79
Earnings Date	Nov 13, 2025

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino ...

• Industry: Pharmaceutical Preparations
• Founded: 1984
• Employees: 4,066
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532482

Financial Performance

In 2024, Granules India's revenue was 44.82 billion, a decrease of -0.55% compared to the previous year's 45.06 billion. Earnings were 5.02 billion, an increase of 23.74%.